Literature DB >> 9451500

Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay.

A Sparreboom1, W J Loos, J Verweij, A I de Vos, M E van der Burg, G Stoter, K Nooter.   

Abstract

This paper describes an analytical procedure for the quantitative determination of the pharmaceutical vehicle Cremophor EL in human plasma samples. The procedure is based on rapid binding of Coomassie brilliant blue G-250 to Cremophor EL following plasma protein precipitation with acetonitrile and analyte extraction with n-butylchloride. The binding of the dye to Cremophor EL causes a shift in the absorption maximum from 465 to 624 nm, which is monitored using an automated microplate-absorbance reader. The assay permits estimation of Cremophor EL concentrations in the range 0.05-1.00% (v/v) in 50 microL of human plasma, with percentage deviation and precision of < or = 12 and < or = 15%, respectively. The assay was subsequently used to measure Cremophor EL concentrations in plasma samples in support of a project to develop a pharmacokinetic model for this compound in patients receiving paclitaxel.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9451500     DOI: 10.1006/abio.1997.2467

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  10 in total

Review 1.  Role of formulation vehicles in taxane pharmacology.

Authors:  L van Zuylen; J Verweij; A Sparreboom
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

Review 2.  Design features for optimization of tetrapyrrole macrocycles as antimicrobial and anticancer photosensitizers.

Authors:  Alejandra Martinez De Pinillos Bayona; Pawel Mroz; Connor Thunshelle; Michael R Hamblin
Journal:  Chem Biol Drug Des       Date:  2017-02       Impact factor: 2.817

Review 3.  Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.

Authors:  Albert J ten Tije; Jaap Verweij; Walter J Loos; Alex Sparreboom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  Stable synthetic bacteriochlorins for photodynamic therapy: role of dicyano peripheral groups, central metal substitution (2H, Zn, Pd), and Cremophor EL delivery.

Authors:  Ying-Ying Huang; Thiagarajan Balasubramanian; Eunkyung Yang; Dianzhong Luo; James R Diers; David F Bocian; Jonathan S Lindsey; Dewey Holten; Michael R Hamblin
Journal:  ChemMedChem       Date:  2012-10-12       Impact factor: 3.466

5.  Effect of valspodar on the pharmacokinetics of unbound paclitaxel.

Authors:  Albert J ten Tije; Timothy W Synold; Darcy Spicer; Jaap Verweij; James H Doroshow; Alex Sparreboom
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

6.  Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia.

Authors:  Sihem Ait-Oudhia; Robert M Straubinger; Donald E Mager
Journal:  Pharm Res       Date:  2012-05-17       Impact factor: 4.200

7.  Photodynamic therapy with decacationic [60]fullerene monoadducts: effect of a light absorbing electron-donor antenna and micellar formulation.

Authors:  Rui Yin; Min Wang; Ying-Ying Huang; Huang-Chiao Huang; Pinar Avci; Long Y Chiang; Michael R Hamblin
Journal:  Nanomedicine       Date:  2013-12-10       Impact factor: 5.307

8.  High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection.

Authors:  Anders Andersen; David J Warren; Paal F Brunsvig; Steinar Aamdal; Gunnar B Kristensen; Harald Olsen
Journal:  BMC Clin Pharmacol       Date:  2006-01-13

9.  Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.

Authors:  O van Tellingen; M T Huizing; V R Panday; J H Schellens; W J Nooijen; J H Beijnen
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

10.  Liquid chromatography/tandem mass spectrometry method for quantitation of cremophor el and its applications.

Authors:  V Vijaya Bhaskar; Anil Middha
Journal:  Int J Anal Chem       Date:  2013-07-28       Impact factor: 1.885

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.